Lecanoric acid mediates anti-proliferative effects by an M phase arrest in colon cancer cells.
Animals
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
CDC2 Protein Kinase
/ metabolism
Cell Cycle Checkpoints
/ drug effects
Cell Line, Tumor
Cell Proliferation
/ drug effects
Colonic Neoplasms
/ drug therapy
Cyclin B1
/ metabolism
Endothelial Cells
/ metabolism
HEK293 Cells
Histones
/ metabolism
Humans
Hydroxybenzoates
/ pharmacology
Lichens
/ chemistry
Mice
Mitosis
NIH 3T3 Cells
Salicylates
/ pharmacology
Atranorin
CDK1
Cyclin B1
Evernic acid
Lecanoric acid
Lichens
M cell cycle arrest
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
12
01
2022
revised:
14
02
2022
accepted:
15
02
2022
pubmed:
23
2
2022
medline:
26
3
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Lichen extracts containing, among other compounds, depsides such as evernic acid, atranorin, and lecanoric acid possess anti-proliferative effects. We aimed to identify lichen metabolites that are responsible for the observed anti-proliferative effects. We performed cytotoxicity, cell colony, cell cycle and apoptosis assays in various cell lines or primary immune cells. We analyzed several cell cycle proteins and apoptosis-related proteins to gain insights into the underlying mechanism. All depsides reduced the viability of the tested cell lines (HCT-116, HEK293T, HeLa, NIH3T3, RAW246.7) in a cell line-dependent manner with lecanoric acid being the most effective. Atranorin did not influence the cell cycle or colony formation in HCT-116 cells, but induced apoptosis in HCT-116 cells. Evernic acid showed no anti-proliferative effects. Lecanoric acid inhibited cell colony formation already at 0.03 µg/ml in HCT-116 cells and induced a G2 cell cycle block in several cell lines. Moreover, lecanoric acid arrested the cell cycle, presumably in the M phase, since expression of cyclin B1 and phosphorylated histone H3 was upregulated, whereas the inactive cyclin-dependent kinase 1 (CDK1) was reduced in HCT-116 cells. Most importantly, cell death induced by lecanoric acid was more prominent in cancer cells than in primary human immune and endothelial cells. In conclusion, lecanoric acid seems to mediate its anti-proliferative effects via arrest of cells in the M phase. Our data suggest lecanoric acid may be a potential new candidate for anti-cancer therapy, because it has anti-proliferative effects on cancer cell lines, and does not affect primary immune cells.
Identifiants
pubmed: 35190352
pii: S0753-3322(22)00122-6
doi: 10.1016/j.biopha.2022.112734
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Cyclin B1
0
Histones
0
Hydroxybenzoates
0
Salicylates
0
atranorin
450U2VJ2VG
lecanoric acid
480-56-8
evernic acid
537-09-7
CDC2 Protein Kinase
EC 2.7.11.22
CDK1 protein, human
EC 2.7.11.22
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
112734Informations de copyright
Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.